A new company which is developing RNA editing therapeutics launched on 19 September with $30 million in initial funding led by ARCH Venture Partners, one of the biotech industry’s largest financiers. The company, AIRNA Corp Inc, plans to use the funds to advance a product candidate to treat the inherited genetic disease alpha-1 antitrypsin deficiency. This is a deficiency that raises a person’s risk of lung disease including the risk of contracting chronic obstructive pulmonary disease. It will also investigate therapies for high unmet needs.
